# NM_153717.3(EVC):c.1895G>C (p.Arg632Pro)

https://sugi.bio/variant/evc-p-arg632pro

## Summary

**EVC p.Arg632Pro (c.1895G>C)** is classified **Uncertain significance** in EVC (ClinVar, Single submitter, 1 submitter; last evaluated 2021-04-09). AlphaMissense: ambiguous (0.3626); Very rare (popmax 0.000424%, nfe); Associated with Ellis-van Creveld syndrome.

**At a glance:** Uncertain significance · review: Single submitter · rsID rs535632933 · 1 submitter · 2 linked conditions · AlphaMissense ambiguous · very rare (popmax 0.000424%, nfe)

## For patients & families {#patients}

This is a change in the EVC gene that is currently of uncertain significance — a definitive interpretation has not yet been established, submitted by 1 submitter, and is linked to Ellis-van Creveld syndrome.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

**Support & next steps:** [Condition overview & support (NIH GARD)](https://rarediseases.info.nih.gov/diseases/0001301/index) · [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [EVC](https://sugi.bio/atlas/gene/EVC/) |
| Protein change (HGVS p.) | p.Arg632Pro |
| Coding change (HGVS c.) | c.1895G>C |
| MANE Select transcript | [NM_153717](https://www.ncbi.nlm.nih.gov/nuccore/NM_153717) |
| dbSNP | [rs535632933](https://www.ncbi.nlm.nih.gov/snp/rs535632933/) |
| Variant type | single nucleotide variant |
| Location | chr4:5797030-5797030 (GRCh38) |
| ClinVar | [VCV1464567](https://www.ncbi.nlm.nih.gov/clinvar/variation/1464567/) |

**All HGVS expressions:** `NC_000004.11:g.5798757G>C`, `NC_000004.12:g.5797030G>C`, `NG_008843.1:g.90834G>C`, `NM_001306090.2:c.1895G>C`, `NM_153717.3:c.1895G>C`

## Computational & population evidence {#evidence}

**Concordance:** AlphaMissense makes no call; SaProt calls this damaging; REVEL does not; AlphaMissense is indeterminate — descriptive only.

- AlphaMissense **ambiguous** (0.3626) — no call either way
- REVEL 0.178 (moderately benign-leaning)
- SaProt LLR -12.755 (damaging)
- → **In-silico consensus:** SaProt calls this damaging; REVEL does not; AlphaMissense is indeterminate
- Conservation: phyloP -2.612, GERP -3.59 — fast-evolving / accelerated position
- CADD: **PHRED 15.35**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- Regional missense constraint: **o/e 1.12** across the covering region of the MANE Select transcript (5,711,381–5,811,034), spanning 99,653 bp. Chi-square p 1.2e-05. Describes the region, not this allele; gnomAD v4.1.1's own constrained determination. *Descriptive; no ACMG code applied.*
- SpliceAI: **below the reporting threshold**. This position is scored for a different substitution (G>T, Δ0.38 acceptor gain), so this allele was evaluated and its deltas all fell under Δ0.2 — a prediction of no splicing effect for this allele, not a gap in our data. *No ACMG code assigned.*
- Population frequency (gnomAD v4.1): grpmax **0.000424%** (nfe) · FAF95 0.000124% · FAF99 9e-05% · 5/1,179,548 in the highest group · 5/1,612,660 alleles overall — very rare (popmax 0.000424%, nfe).

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**EVC** population constraint: LOEUF 1.134, pLI 6.2955e-37, missense-Z -1.5572. *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

Curated gene–disease validity (ClinGen):

- **Ellis-van Creveld syndrome** — Definitive (AR)

## Protein context {#protein}


AlphaFold model confidence (whole protein): pLDDT 74.49, 41% of residues very-high.

## What this gene does {#gene-function}

*Describes the biological roles of EVC (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*


### Pathways affected {#pathways}

EVC participates in **2 Reactome pathways** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| [Hedgehog 'on' state](https://reactome.org/content/detail/R-HSA-5632684) | curated |
| [Activation of SMO](https://reactome.org/content/detail/R-HSA-5635838) | electronic |

## Clinical significance {#significance}

**Uncertain significance** — review status Single submitter *(criteria provided, single submitter)*, last evaluated 2021-04-09.

**Submitter consensus:** unanimous (1/1 Uncertain significance).

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Labcorp Genetics (formerly Invitae), Labcorp | Uncertain significance | criteria provided, single submitter | clinical testing | 2021-04-09 |

## Associated conditions {#conditions}

[Ellis-van Creveld syndrome](https://sugi.bio/atlas/disease/ellis-van-creveld-syndrome/), [acrofacial dysostosis, Weyers type](https://sugi.bio/atlas/disease/acrofacial-dysostosis-weyers-type/).

**Reported phenotype names (ClinVar):** Ellis-van Creveld syndrome, Curry-Hall syndrome, Chondroectodermal dysplasia, MESOECTODERMAL DYSPLASIA, EVC-Related Ellis-van Creveld Syndrome, EVC2-Related Ellis-van Creveld Syndrome, WEYERS ACRODENTAL DYSOSTOSIS.

## Similar variants {#similar}

Related EVC variant pages (same residue, condition, or type): [EVC p.Arg632Gln](/variant/evc-p-arg632gln), [EVC p.Arg632Trp](/variant/evc-p-arg632trp), [EVC p.Arg632=](/variant/evc-p-arg632), [EVC c.1098+1G>A](/variant/evc-c-1098-plus-1g-a), [EVC c.175-2A>G](/variant/evc-c-175-minus-2a-g), [EVC c.1777-1G>A](/variant/evc-c-1777-minus-1g-a), [EVC c.1777-2A>G](/variant/evc-c-1777-minus-2a-g), [EVC c.1886+1G>C](/variant/evc-c-1886-plus-1g-c).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-14); gnomAD v4.1 (Broad Institute, built 2026-10-14); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-10-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 1464567). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*